BioDrugs

, Volume 32, Issue 2, pp 137–138 | Cite as

Correction to: Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years’ Experience Gained

  • Matti Aapro
  • Andriy Krendyukov
  • Martin Schiestl
  • Pere Gascón
Correction
  • 783 Downloads

1 Correction to: BioDrugs  https://doi.org/10.1007/s40259-018-0262-9

Figure 1, HX575 column, 5th box down, which previously read “SC HX575 vs. Eprex®/Erypo® 417 patients with CKD-related anemia” as shown here,
should read “SC HX575 417 patients with CKD-related anemia” as shown below.

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Matti Aapro
    • 1
  • Andriy Krendyukov
    • 2
  • Martin Schiestl
    • 3
  • Pere Gascón
    • 4
  1. 1.Institut Multidisciplinaire d’Oncologie, Clinique de GenolierGenolierSwitzerland
  2. 2.Hematology/NephrologySandoz Biopharmaceuticals, HEXAL AGHolzkirchenGermany
  3. 3.Sandoz Biopharmaceuticals, Sandoz International GmbHKundlAustria
  4. 4.Department of Hematology-Oncology, Hospital Clínic de BarcelonaUniversity of BarcelonaBarcelonaSpain

Personalised recommendations